The goal of this clinical trial Is conducted to evaluate the efficacy and safety of active or sham HD-tDCS in combination with dexmedetomidine in patients with moderate to severe ARDS due to COVID-19 with delirium in intensive care unit (ICU). The hypothesis was that HD-tDCS combined with concomitant dexmedetomidine would reduce delirium rates.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Enrollment
40
Brain stimulation using active high definition transcranial direct current stimulation is applied simultaneously with the use of dexmedetomidine as a pharmacological treatment for delirium in critical illness patients with covid-19
Sham high definition transcranial direct current stimulation is applied simultaneously with the use of dexmedetomidine as a pharmacological treatment for delirium in critical illness patients with covid-19
Federal University of Paraiba
João Pessoa, Paraíba, Brazil
Delirium Severity
delirium severity over the 28-day study period is measured using the CAM-ICU-7. Patients discharged before 28 days were considered without delirium.
Time frame: 28 days
length of stay in the ICU and hospital stay
defined as the total number of days that patients remained in the hospital from the date of randomization to the date of hospital discharge
Time frame: 28 days
Occurrence of hypotension requiring any vasopressor administration
Time frame: 28 days
C-reactive protein levels
Time frame: 28 days
ventilator-free days during the first 28 days
defined as the number of days free from mechanical ventilation for at least 48 consecutive hours
Time frame: 28 days
Exploratory analisys
Organ dysfunction and clinical response; use of Concomitant Medications; Richmond Agitation Sedation Scale (RASS) and mortality prognosis
Time frame: 28 days
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.